Detailed Information
Cited 6 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
A phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, rivoceranib, for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC).
- Authors
- Kang, H[Kang, Hyunseok]; Ahn, MJ[Ahn, Myung-Ju]; Muzaffar, J[Muzaffar, Jameel]; Keam, B[Keam, Bhumsuk]; Bowles, DW[Bowles, Daniel W.]; Wong, DJL[Wong, Deborah J. L.]; Ho, AL[Ho, Alan Loh]; Kim, SB[Kim, Sung-Bae]; Worden, FP[Worden, Francis P.]; Yun, T[Yun, Tak]; Sari, S[Sari, Suha]; Conlan, MG[Conlan, Maureen G.]; Hanna, GJ[Hanna, Glenn J.]
- Issue Date
- 1-Jun-2022
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.40, no.16
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 40
- Number
- 16
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.